Study of common bacterial and fungal pathogens in children with hematological malignancies during febrile neutropenia: Single center egyptian study

Infectious Disorders - Drug Targets

Volumn 16, Issue 1, 2016, Pages 54-62

  Hagag, Adel A ^a   Hassan, Samir M ^a   Elgamasy, Mohamed A ^a   Afifi, Ibtesam K ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Bacterial and fungal pathogens; Febrile neutropenia; Hematological malignancies

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN; AMPICILLIN; AZITHROMYCIN; CEFALEXIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; ERYTHROMYCIN; FLUCONAZOLE; IMIPENEM; OXACILLIN; PENICILLIN G; SULTAMICILLIN; VANCOMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTERIUM; BACTERIUM ISOLATE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CEREBROSPINAL FLUID ANALYSIS; CHILD; CONTROLLED STUDY; DISK DIFFUSION; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; FUNGUS; FUNGUS GROWTH; FUNGUS ISOLATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHODGKIN LYMPHOMA; NONHUMAN; PSEUDOMONAS; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; THROAT CULTURE; BACTEREMIA; CANDIDA; DRUG EFFECTS; EGYPT; EVALUATION STUDY; GROWTH, DEVELOPMENT AND AGING; HEMATOLOGIC DISEASE; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOGENICITY; PHARYNX; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; AMPICILLIN; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTEREMIA; BLOOD CELL COUNT; CANDIDA; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; EGYPT; FEBRILE NEUTROPENIA; FEMALE; FUNGI; GRAM-NEGATIVE BACTERIA; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; PHARYNX; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84974724292     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526516666151230124333     Document Type: Article

References (38)

1. Esparza, S.D; Samuel, Sakamoto, K.M. Topics in Pediatric Leukemia-Acute lymphoblastic leukemia. Med Gem Med., 2005, 7 (l), 23.
2. Hagag, A.A.; AbdElaal, A.M.; Elfaragy, M.S.; Hassan, S.M.; Elzamarany E.A. Therapeutic Value of Black Seed Oil in Methotrexate Hepatotoxicity in Egyptian Children with Acute Lymphoblastic Leukemia. Infect Disord Drug Targets, 2015, 15(1), 64-71.
3. Toma, P.; Granata, C.; Rossi, A.; Garaventa A. Multimodality imaging of Hodgkin disease and non-Hodgkin lymphomas in children. Radio Graphics, 2007, 27, 1335-1354.
4. Hughes, W.T.; Armstrong, D.; Bodey, G.P.; Bow, E.J.; Brown, A.E.; Calandra, T.; Feld, R.; Pizzo, P.A.; Rolston, K.V.; Shenep, J.L; Young, L.S. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis., 2002, 34, 730-51.
5. Walsh, T.J.; Teppler, H.; Donowitz, G.R.; Maertens, J.A.; Baden, L.R.; Dmoszynska, A.; Cornely, O.A.; Bourque, M.R.; Lupinacci, R.J.; Sable, C.A.; DePauw, B.E. Caspofungin versus liposomal AMB for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl. J. Med., 2004, 351, 1391-1402.
6. Danilatou, V.; Mantadakis, E.; Galanakis, E.; Christidou, A.; Stiakaki, E.; Kalmanti, M. Three cases of viridans group streptococcal bacteremia in children with febrile neutropenia and literature review. Scand J. Infect Dis., 2003, 35, 873-876.
7. Paulus, S.; Dobson, S. Febrile neutropenia in children with cancer. Adv. Exp. Med. Biol., 2009, 634, 185-204.
8. Garnica, M.; Nucci, M. Epidemiology, treatment and prophylaxis of infections in chronic lymphocytic leukemia. Rev. Bras. Hematol. Hemoter., 2005, 27, 290-300.
9. Greenberg, D.; Moser, A.; Yagupsky, P.; Peled, N.; Hofman, Y.; Kapelushnik, J.; Leibovitz, E. Microbiological spectrum and susceptibility patterns of pathogens causing bacteremia in pediatric febrile neutropenic oncology patients: Comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int. J. Antimicrob. Agents., 2005, 25, 469-73.
10. Viscoli, C.; Castagnola, E. Prophylaxis and empirical therapy for infection in cancer patients. In: Principles and Practice of infectious diseases. Mandell GL, Bennett JE and Doolin R, Eds.; Churchill Livingstone: Philadelphia, 2005; pp.3442-3462.
11. Conen, K. Fever with chemotherapy induced neutropenia. Ther Umsch., 2014, 71(1), 17-22. doi: 10.1024/0040-5930/a000477. [Article in German].
12. Cheesbrough, M. Biochemical tests to identify bacteria and bacterial pathogens in: District Laboratory Practice in Tropical Countries. Monica Cheesbrough, Ed.; 2nd ed. Press syndicate of Cambridge University, 2005; Part 2, Chapter 7.18, pp. 157-234.
13. Collee, J.G.; Miles, R.S. Tests of identification of bacteria. In practical Medical microbiology. Collee J.G., Duguid J.P., Faraser A.G., Marmion B.P, Eds.; 13th ed. 1996; pp.8-141.
14. National Committee for Clinical Laboratory Standards (NCCLS): Performance standards for antimicrobial susceptibility testing. 18th informational supplement 2008; Vol 28, No 1. CLSI Wayne, PA. Formerly National Committee for Clinical Laboratory Standards recently Clinical Laboratory Standards Institute (CLSI) also available at jvdi.org/cgi/content/ full/21/1/53.
15. Clinical and Laboratory Standards Institute/NCCLS. Methods for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline. CLSI/NCCLS document M44-A [ISBN 1-56238-532-1].Clinical and Laboratory Standards Institute/NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004.
16. Lee, S.C.; Lo, H.G.; Fung, C.P.; Lee, N.; See, L.C. Disc diffusion test and E-test with enriched Muller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J. Microbiol. Immunol. Infect., 2009, 42, 148-153.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. CLSI document M100-S16 [ISBN 1-56238-588-7]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006.
18. Clinical and Laboratory Standards Institute. Zone Diameter Interpretive Standards and Corresponding Minimal Inhibitory Concentration (MIC) Interpretive Breakpoints; Informational Supplement. M44-S1. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2005.
19. Kiraz, N.; Dag, I.; Oz, Y.; Yamac, M.; Kiremitci, A.; Kasifoglu, N. Correlation between broth microdilution and disk diffusion methods for antifungal sus ceptibility testing of caspofungin, voriconazole, amphotericin B, itraconazole and fluconazole against Candida glabrata. J. Microbiol. Methods, 2010, 82(2), 136-140.
20. Hooton, T.M.; Bradley, S.F.; Cardenas, D.D. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin. Infect. Dis., 2010, 50(5), 625-663.
21. Mandell, L.A.; Wunderink, R.G.; Anzueto, A.; Bartlett, J.G.; Campbell, G.D.; Dean, N.C. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis., 2007, 44(2), S27-72.
22. Rose, A. M.; J. E. Mueller, S. Gerst, B. M. Njanpop-Lafourcade, A. L. Page, P. Nicolas. Meningitis dipstick rapid test: evaluating diagnostic performance during an urban Neisseria meningitidis serogroup A outbreak, Burkina Faso, 2007. PLoS ONE, 2010, 5(6), e11086. doi:10.1371/journal.pone.0011086.
23. Villafuerte-Gutierrez P.; Villalon, L.; Losa, J.E.; Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol., 2014, 2014:986938. doi: 10.1155/2014/986938. Epub 2014 Nov 27.
24. Walter, T. Hughes; Donald, Armstrong.; Gerald, P. Bodey.; Arthur, E. Brown.; John, E. Edwards.; Ronald, Feld.; Philip, Pizzo.; Kenneth, V. I. Rolston.; Jerry, L. Shenep.; Lowell, S. Young. Clinical Infectious Diseases. Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever. Clin. Infect. Dis., 1997, 25(3), 551-573.
25. Keng, M.K.; Sekeres, M.A. Febrile neutropenia in hematologic malignancies. Curr. Hematol. Malig. Rep., 2013, 8(4), 370-8. doi: 10.1007/s11899-013-0171-4.
26. Mandal, P.K.; Maji, S.K.; Dolai T.K.; De R, Dutta S.; Saha, S.; Bhattacharyya M. Micro-organisms associated with febrile Neutropenia in Patients with Haematological Malignancies in a Tertiary Care Hospital in Eastern India Indian J Hematol Blood Transfus., 2015, 31(1), 46-50. doi: 10.1007/s12288-014-0393-1. Epub 2014 May 4.
27. Roongpoovapatr P, Suankratay C. Causative pathogens of fever in neutropenic patients at King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 2010, 93(7), 776-83.
28. Walwyn M, Nicholson A, Lee MG, Wharfe G, Frankson MA. Febrile neutropaenia in cancer patients. West Indian Med. J., 2010, 59(2), 209-14.
29. Nabil Ahmed, Hadir A. El-Mahallawy, Ibrahim A Ahmed, Shimaa Nassif, Amal El-Beshlawy and Alaa El-Haddad. National Cancer Institute, Cairo University, Cairo, Egypt. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia. Pediatr. Blood Cancer, 2007, 49, 786-792.
30. Freifeld, A.G.; Bow, E.J.; Sepkowitz, K.A.; Boeckh, M.J.; Ito, J.I.; Mullen, C.A.; Raad, I.I.; Rolston, K.V.; Young, J.A.; Wingard, J.R. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin. Infect. Dis., 2011, 52(4), e56-93. doi: 10.1093/cid/cir073.
31. Corapcioglu F.; Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: A prospective randomized trial of the treatment efficacy and cost. Pediatr. Hematol. Oncol., 2005, 22(1), 59-70.
32. Sigurdardottir, K.; Digranes, A.; Harthug, S.; Nesthus, I.; Tangen, J.M.; Dybdahl, B. A multicentre prospective study of febrile neutropenia in Norway: Microbiological findings and antimicrobial susceptibility. Scand J. Infect Dis., 2005, 37, 455-464.
33. Alberth, M.; Majoros, L.; Kovalecz, G.; Borba's, E.; Szegedi, I.; Marton, I.J.; Kiss, C. Significance of oral Candida infections in children with cancer. Pathol Onco Res, 2006, 12(4), 237-41.
34. Badiee, P.; Kordbacheh P.; Alborzi, A.; Malekhoseini, S.; Ramzi, M.; Mirhendi, H.; Mahmoodi, M.; Shakiba, E. Study on invasive fungal infections in immunocompromised patients to present: A suitable early diagnostic procedure. Int. J. Infect. Dis., 2009, 13(1), 97-102.
35. Sánchez-Vargas L.O.; Ortiz-López N.G.; Villar M.; Moragues M.D.; Aguirre J.M.; Cashat-Cruz M.; Lopez-Ribot J.L.; Gaitán-Cepeda L.A.; Quindós G. Point prevalence, microbiology and antifungal patterns of oral Candida isolates colonizing or infecting Mexicam HIV/AIDS patients and healthy persons. Rev. Iberoam. Micol., 2005, 22, 83-92.
36. Magill, S.S.; Shields, C.; Sears, C.L.; Choti, M.; Merz W.G. Triazole cross resistance among Candida spp. Case report, occurrence among blood stream isolates, and implications for antifungal therapy. J. Clin. Microbiol., 2006, 44(2), 529-535.
37. Carrillo-Muñoz A.J.; Quindós G.; del Valle O.; Santos P.; Giusiano G.; Ezkurra P.A.; Estivill M.D., Casals J.B. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by CLSI M-44A disk diffusion method with Neo-Sensitabs tablets. Chemotherapy, 2008, 54(1), 38-42.
38. Mandras, N.; Tullio, V.; Allizond, V.; Scalas, D.; Banche, G.; Roana, J.; Robbiano, F.; Giacomo Fucale; Malabaila, A.; Cuffini, A.M.; Carlone, N. In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. Determined by disk diffusion testing in Turin, Italy. Antimicrob. Agents Chemother., 2009, 53(4), 1657-1659.